A Long-term Extension Study for the Phase 3 Study of Nalmefene (339-14-001) in Patients With Alcohol Dependence
Status:
Completed
Trial end date:
2017-01-18
Target enrollment:
Participant gender:
Summary
The long-term safety and efficacy of nalmefene hydrochloride at 20 mg in patients with
alcohol dependence will be evaluated in a multicenter, open-label, uncontrolled trial.